Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.68 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.51 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232412 | 0.90 | MAPK10 (0.67) | MAPK10MAPK9PTK2FGFR1ZAP70 | |
| SCHEMBL2183646 | 0.85 | MAPK10 (0.70) | MAPK10MAPK9PTK2FGFR1MAPK3 | |
| SCHEMBL1232329 | 0.83 | MAPK10 (0.85) | MAPK10MAPK9PTK2 | |
| SCHEMBL1231859 | 0.81 | MAPK10 (1.00) | MAPK10MAPK9PTK2 | |
| SCHEMBL1232326 | 0.81 | MAPK10 (0.83) | MAPK10MAPK9PTK2FGFR1ZAP70 | |
| SCHEMBL47302 | 0.80 | MAPK10 (0.84) | MAPK10MAPK9PTK2FGFR1ZAP70 | |
| SCHEMBL1231775 | 0.80 | MAPK10 (1.00) | MAPK10MAPK9PTK2 | |
| SCHEMBL12900862 | 0.80 | MAPK3 (0.58) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL1231877 | 0.79 | MAPK10 (0.70) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL1231705 | 0.79 | MAPK10 (0.85) | MAPK10MAPK9PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK10 590/4885MAPK9 239/4885PTK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.